Aro Biotherapeutics
PrivateLast Round
Series B
Nov 28, 2023
Total Funding Raised
$142.5M
Company Overview
Aro Biotherapeutics is a biopharmaceutical company that develops a protein drug platform aimed at harnessing the potential of genetic medicines through small, non-antibody protein scaffolds designed for targeted therapeutic applications in non-small cell lung cancer and other serious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aro Biotherapeutics Comps
Public and private peers based on sector, stage, and business model.
Aro Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 28, 2023 | ||||
| Series A | Jan 5, 2021 | ||||
| Seed | Dec 11, 2018 |
Key People
Founding team and executive leadership
Aro Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioMotiv | Seed, Series A |
| Ridgeback Capital | Series A |
| TD Securities | Series A, Series B |
| HealthCap | Series A, Series B |
| Anthelion Capital | Series A, Series B |
| BVF Partners L.P. | Series A, Series B |
| Northpond Ventures | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 19, 2026
ABX1100, a targeted genetic therapy, is advancing in the rare disease pipeline.
- Jan 7, 2025
Glenn Crater, MD, appointed as new Chief Medical Officer.
Aro Biotherapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Aro Biotherapeutics's valuation, stock price, and market status.
